Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Varying VRd regimens in real-world patients

Surbhi Sidana • 14 Sep 2019
IMW 2019
Multiple Myeloma Bortezomib Dexamethasone Lenalidomide

Surbhi Sidana, MBBS Mayo Clinic, Rochester, MN, presents results on investigations into different regiments of bortezomib, lenalidomide, dexamethasone (VRd) and their efficacy and toxicity in real-world patients at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Surbhi Sidana

Managing toxicities associated with immunotherapy in multiple myeloma
1:29
Managing toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
Ide-cel therapy for multiple myeloma with renal impairment
1:43
Ide-cel therapy for multiple myeloma with renal impairment
Surbhi Sidana • 8 Dec 2023
An overview of the toxicities associated with immunotherapy in multiple myeloma
3:09
An overview of the toxicities associated with immunotherapy in multiple myeloma
Surbhi Sidana • 8 Dec 2023
Real-world outcomes of ide-cel in heavily pre-treated R/R MM
1:59
Real-world outcomes of ide-cel in heavily pre-treated R/R MM
Surbhi Sidana • 8 Dec 2023

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
Surbhi Sidana • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
Surbhi Sidana • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Surbhi Sidana • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Surbhi Sidana • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals